Intelligent Bio Solutions
INBS
8 hedge funds and large institutions have $437K invested in Intelligent Bio Solutions in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0% more funds holding
Funds holding: 8 → 8 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.42% less ownership
Funds ownership: 1.01% → 0.59% (-0.42%)
28% less capital invested
Capital invested by funds: $606K → $437K (-$169K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$321K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.69K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$639 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$94 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$161K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$160K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Alyeska Investment Group
Chicago,
Illinois
| $357K | +$321K | +20,620 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $39.3K | +$5.69K | +365 | +19% |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $26.8K | – | – | – |
|
|
ACM
4
ADAR1 Capital Management
Austin,
Texas
| $9.32K | -$160K | -10,286 | -95% |
|
|
5
UBS Group
Zurich,
Switzerland
| $2.68K | -$10.6K | -677 | -81% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $1.84K | +$639 | +41 | +63% |
|
7
Bank of America
Charlotte,
North Carolina
| $43 | – | – | – |
|
|
ACM
8
Altium Capital Management
New York
| – | -$161K | -8,391 | Closed |
|
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$94 | +6 | New |
|
INBS Hedge Fund Activity: Q3 2024 in Review
8 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Intelligent Bio Solutions (INBS) for Q3 2024, worth a combined $437K — down 28% from $606K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new INBS positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $321K. The largest seller was Altium Capital Management, exiting entirely with an estimated $161K sold.
- 8 institutional investors held Intelligent Bio Solutions (INBS) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $437K of Intelligent Bio Solutions stock for Q3 2024, down 28% quarter-over-quarter.
- 2 funds opened new Intelligent Bio Solutions positions in Q3 2024 and 1 closed out, a net change of +1 holder.
- The largest Intelligent Bio Solutions buyer in Q3 2024 was Alyeska Investment Group, an estimated $321K added.
- The largest Intelligent Bio Solutions seller in Q3 2024 was Altium Capital Management, an estimated $161K sold.
Based on aggregated 13F filings for Q3 2024.